Three sides of the same coin: Measuring global cognitive impairment with the MMSE, ADAS-cog and CAMCOG

International Journal of Geriatric Psychiatry

Volumn 25, Issue 8, 2010, Pages 770-779

  Wouters, Hans ^a   Van Gool, Willem A ^a   Schmand, Ben ^a   Zwinderman, Aeilko H ^a   Lindeboom, Robert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cognitive assessment; Dementia; Epidemiology; Psychometrics

Indexed keywords

AGED; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE PART; ARTICLE; CAMBRIDGE COGNITIVE EXAMINATION; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLOBAL COGNITIVE DEFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; RASCH ANALYSIS; SCORING SYSTEM; VALIDITY;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 77955403230     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2402     Document Type: Article

References (30)

1. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edn. American Psychiatric Association: Washington, DC.
2. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. 2005. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19: 520-531.
3. Ballard C, Patel A, Oyebode F, Wilcock G. 1996. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age Ageing 25: 209-213.
4. Fillenbaum GG, George LK, Blazer DG. 1988. Scoring nonresponse on the Mini-Mental State Examination. Psychol Med 18: 1021-1025.
5. Fischer GH, Molenaar IW. 1995. Rasch Models: Foundations, Recent Developments and Applications. Springer-Verlag: New York.
6. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. 2007. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68: 1588-1595.
7. Folstein MF, Folstein SE, McHugh PR. 1975. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
8. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. 2007. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105.
9. Holman R, Lindeboom R, Glas CAW, Vermeulen M, de Haan RJ. 2003. Constructing an item bank using Item Response Theory: the AMC linear disability score project. Health Serv Outcomes Res Methodol 4: 19-33.
10. Jenkinson C, Norquist JM, Fitzpatrick R. 2003. Deriving summary indices of health status from the Amyotrophic Lateral Sclerosis Assessment Questionnaires (ALSAQ-40 and ALSAQ-5). J Neurol Neurosurg Psychiatry 74: 242-245.
11. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. 1998. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 55: 1065-1069.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944.
13. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. 1997. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S13-S21.
14. Mungas D, Reed BR, Kramer JH. 2003. Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons. Neuropsychology 17: 380-392.
15. Nielsen H, Lolk A, Andersen K, Andersen J, Kragh-Sorensen P. 1999. Characteristics of elderly who develop Alzheimer's disease during the next two years: a neuropsychological study using CAMCOG. The Odense Study. Int J Geriat Psychiatry 14: 957-963.
16. Raskind MA, Peskind ER, Wessel T, Yuan W. 2000. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268.
17. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
18. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R. 1986. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698-709.
19. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L. 2004. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63(12): 2341-2347.
20. Schmand B, Walstra G, Lindeboom J, Teunisse S, Jonker C. 2000. Early detection of Alzheimer's disease using the Cambridge Cognitive Examination (CAMCOG). Psychol Med 30: 619-627.
21. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. 2000. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol 57: 839-844.
22. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. 1994. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390-396.
23. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-2276.
24. Tierney MC, Yao C, Kiss A, McDowell I. 2005. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 64: 1853-1859.
25. Tombaugh TN, McIntyre NJ. 1992. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40: 922-935.
26. Van der Flier WM, Van Den Heuvel DM, Weverling-Rijnsburger AW, Spilt A, Bollen EL, Westendorp RG, Middelkoop HA, van Buchem MA. 2002. Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology 59: 874-879.
27. Verhelst ND, Glas CAW. 1995. The one parameter logistic model. In Rasch Models, Foundations, Recent Developments and Applications, Fischer GH, Molenaar IW (eds). Springer Verlag: New York; 215-237.
28. Walstra GJ, Teunisse S, Van Gool WA, Van Crevel H. 1997. Reversible dementia in elderly patients referred to a memory clinic. J Neurol 244: 17-22. (Pubitemid 26413893)
29. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 321: 1-7.
30. Wouters H, Van Gool WA, Schmand B, Lindeboom R. 2008. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 22: 236-244.